Amgen's denosumab shows promise in small, NIH-funded rare bone disease study

Amgen’s Prolia/Xgeva (denosumab) could have another use in a rare bone disease, according to a small NIH-funded Phase II study, adding to its approvals in other bone disorders as biosimilar competition is on its way.